MCID: GST030
MIFTS: 44

Gastrinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Gastrinoma

MalaCards integrated aliases for Gastrinoma:

Name: Gastrinoma 12 55 44 15 73
Gastrin Secreting Tumor 12
Gastrinoma, Malignant 73
Malignant Gastrinoma 12
Gastrin Cell Tumour 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5577
MeSH 44 D015408
NCIt 50 C3050

Summaries for Gastrinoma

Disease Ontology : 12 A neuroendocrine tumor that results in an overproduction of gastric acid.

MalaCards based summary : Gastrinoma, also known as gastrin secreting tumor, is related to pancreatic gastrinoma and duodenal gastrinoma. An important gene associated with Gastrinoma is MEN1 (Menin 1), and among its related pathways/superpathways are Signaling by GPCR and Gastric acid production. The drugs SecreFlo and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include liver, pancreas and testes, and related phenotype is endocrine/exocrine gland.

Wikipedia : 76 A gastrinoma is a tumor in the pancreas or duodenum that secretes excess of gastrin leading to... more...

Related Diseases for Gastrinoma

Diseases related to Gastrinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)
# Related Disease Score Top Affiliating Genes
1 pancreatic gastrinoma 33.1 MEN1 SCT SST
2 duodenal gastrinoma 31.8 CHGA GAST MEN1 SCT SST
3 zollinger-ellison syndrome 31.5 CHGA GAST MEN1 SCT SST
4 duodenitis 31.4 GAST INS
5 multiple endocrine neoplasia 31.0 CHGA MEN1
6 pernicious anemia 30.1 GAST SST
7 peptic ulcer disease 30.0 GAST MEN1 SCT
8 ectopic cushing syndrome 29.9 MEN1 SST
9 hyperparathyroidism 29.8 CHGA GAST MEN1
10 phaeochromocytoma 29.8 CHGA SST
11 atrophic gastritis 29.7 CHGA GAST SST
12 neuroendocrine tumor 29.5 CHGA GAST MEN1 SST
13 mixed ductal-endocrine carcinoma 29.5 CHGA GAST SST
14 carcinoid syndrome 29.3 CHGA MEN1 SST
15 duodenal ulcer 29.2 GAST INS SCT SST
16 insulinoma 28.5 CHGA INS MEN1 SCT SST
17 glucagonoma 28.3 CHGA SCT SST VIP
18 multiple endocrine neoplasia, type i 28.2 CHGA GAST INS MEN1 SCT SST
19 somatostatinoma 27.7 CHGA INS SST VIP
20 islet cell tumor 26.4 CHGA GAST INS MEN1 SST VIP
21 gastric gastrinoma 12.1
22 pancreatic neuroendocrine tumor 11.3
23 diphyllobothriasis 10.5 GAST SCT
24 autoimmune atrophic gastritis 10.5 CHGA GAST
25 goblet cell carcinoid 10.5 CHGA GAST
26 non-functioning pancreatic endocrine tumor 10.5 CHGA GAST
27 pylorospasm 10.4 GAST SST
28 postcholecystectomy syndrome 10.4 GAST SST
29 pancreatitis 10.4
30 retinitis pigmentosa 40 10.4 GAST SST
31 tanycytic ependymoma 10.4 CHGA MEN1
32 hepatitis 10.4
33 hyperproinsulinemia 10.4 INS SCT
34 angiodysplasia 10.4 SCT SST
35 pancreatic somatostatinoma 10.4 MEN1 SST
36 hormone producing pituitary cancer 10.3 MEN1 SST
37 adenoma of the pancreas 10.3 CHGA SST
38 gastrointestinal neuroendocrine tumor 10.3 CHGA SST
39 functioning pituitary adenoma 10.3 MEN1 SST
40 steatorrhea 10.3 SCT SST
41 pituitary carcinoma 10.3 CHGA SST
42 duodenum cancer 10.3 MEN1 SST
43 pancreatoblastoma 10.3 CHGA SST
44 stomach disease 10.3 GAST SST
45 duodenal somatostatinoma 10.2 INS SST
46 postural hypotension 10.2 INS SST
47 granulosa cell tumor of the ovary 10.2 CHGA INS
48 endocrine organ benign neoplasm 10.2 MEN1 SST
49 hyperpituitarism 10.2 INS SST
50 pituitary tumors 10.2 MEN1 SST

Graphical network of the top 20 diseases related to Gastrinoma:



Diseases related to Gastrinoma

Symptoms & Phenotypes for Gastrinoma

MGI Mouse Phenotypes related to Gastrinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.02 CHGA GAST INS MEN1 VIP

Drugs & Therapeutics for Gastrinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
SecreFlo 18 SECRETIN SECRETIN SYNTHETIC PORCINE Repligen April 2002

Drugs for Gastrinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lansoprazole Approved, Investigational Phase 4,Phase 1 103577-45-3 3883
2
Pantoprazole Approved Phase 4,Phase 2 102625-70-7 4679
3
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
4
Dexlansoprazole Approved, Investigational Phase 4,Phase 1 138530-94-6, 103577-45-3 9578005
5 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
6 Antacids Phase 4,Phase 3,Phase 2,Phase 1
7 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
8 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1
9
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
10
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
11
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
12
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
13
Esomeprazole Approved, Investigational Phase 3,Phase 1 161796-78-7, 119141-88-7 4594 9579578
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
leucovorin Approved, Nutraceutical Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 143 6006
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
17 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 59763-91-6
18 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
19 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
20 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
21 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
22 Antimetabolites Phase 2, Phase 3,Phase 1
23 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
24 Analgesics Phase 3
25 Central Nervous System Depressants Phase 3
26 Adjuvants, Anesthesia Phase 3
27 Cinacalcet Hydrochloride Phase 3
28 Narcotics Phase 3
29 Analgesics, Opioid Phase 3
30 Anesthetics Phase 3
31 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
32 Anesthetics, General Phase 3
33 Anesthetics, Intravenous Phase 3
34 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
36 Peripheral Nervous System Agents Phase 3
37 Calcimimetic Agents Phase 3
38 Calcium, Dietary Phase 3,Phase 2,Phase 1
39 Folate Nutraceutical Phase 2, Phase 3
40 Vitamin B9 Nutraceutical Phase 2, Phase 3
41 Cola Nutraceutical Phase 3,Phase 1
42
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
43
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
44
Doxorubicin Approved, Investigational Phase 2,Not Applicable 23214-92-8 31703
45
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
46
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
47
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
48
Omeprazole Approved, Investigational, Vet_approved Phase 2,Phase 1 73590-58-6 4594
49
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
50
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
2 A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
3 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
4 Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome Completed NCT00079833 Phase 3 Esomeprazole magnesium (Nexium)
5 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3 D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
6 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
9 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
10 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2 Pantoprazole;Omeprazole
11 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
12 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
13 Effect of G17DT in Patients With Stage II/III Colorectal Cancer Completed NCT02518373 Phase 2 Omeprazole
14 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
15 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
16 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
17 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
18 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
19 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
20 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
21 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
22 EPO906 in Carcinoid and Other Neuroendocrine Tumors Completed NCT00050349 Phase 2 EPO906 epothilone B
23 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2 regorafenib
24 Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Active, not recruiting NCT01229943 Phase 2 Everolimus;Octreotide Acetate
25 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
26 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
27 YF476 and Type II Gastric Carcinoids Enrolling by invitation NCT02454075 Phase 2 YF476
28 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
29 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2 everolimus
30 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
31 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
32 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
33 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2 dovitinib lactate
34 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
35 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
36 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
37 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
38 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
39 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
40 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
41 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
42 A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants. Completed NCT00942175 Phase 1 Clopidogrel;Clopidogrel and Lansoprazole;Clopidogrel and Dexlansoprazole;Clopidogrel and Omeprazole;Clopidogrel and Esomeprazole
43 Laser Tissue Welding - Distal Pancreatectomy Sealing Study Recruiting NCT03147768 Phase 1
44 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
45 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
46 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376
47 Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome Completed NCT00001254
48 Treatment of Zollinger-Ellison Syndrome Completed NCT00001241
49 Nexium Capsules Clinical Experience Investigation Completed NCT01434485
50 Evaluating Patients With Abnormal Levels of Gastric Acid Completed NCT00001240

Search NIH Clinical Center for Gastrinoma

Cochrane evidence based reviews: gastrinoma

Genetic Tests for Gastrinoma

Anatomical Context for Gastrinoma

MalaCards organs/tissues related to Gastrinoma:

41
Liver, Pancreas, Testes, Small Intestine, Lymph Node, Bone, Breast

Publications for Gastrinoma

Articles related to Gastrinoma:

(show top 50) (show all 436)
# Title Authors Year
1
Gastrinoma and Zollinger-Ellison syndrome in canids: a literature review and a case in a Mexican gray wolf. ( 29860931 )
2018
2
Disease Control on Lanreotide AutogelAr 120 mg in a Patient with Metastatic Gastrinoma: A Case Report. ( 29430219 )
2017
3
Severe chronic diarrhoea secondary to primary lymph node gastrinoma. ( 28446479 )
2017
4
Gastroduodenal neuroendocrine neoplasms, including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). ( 28540972 )
2017
5
Duodenal Gastrinoma Discovered on Evaluation for Incidental Gastric Carcinoid. ( 28300688 )
2017
6
A primary hepatic gastrinoma accompanied by hyperplasia of multi-nodular Brunner's glands. ( 29181825 )
2017
7
The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma? ( 29019150 )
2017
8
Gastrinoma ( 28722872 )
2017
9
Long-Term Efficacy of S-1 Chemotherapy plus Administration of Octreotide for a Patient with Metastatic Neuroendocrine Tumor (Gastrinoma). ( 28626400 )
2017
10
Primary lymph node gastrinoma: A single institution experience. ( 28705492 )
2017
11
Acute kidney injury following vomiting and diarrhea after endoscopy in a duodenal gastrinoma patient. ( 28070096 )
2017
12
(68)Ga-DOTATOC-PET/CT for effective diagnosis and treatment of pancreatic tail gastrinoma with multiple liver metastases: a case report. ( 26743558 )
2016
13
The Selective Arterial Calcium Injection Test is a Valid Diagnostic Method for Invisible Gastrinoma with Duodenal Ulcer Stenosis: A Case Report. ( 27348901 )
2016
14
Clinical treatment of gastrinoma: A case report and review of the literature. ( 27123130 )
2016
15
Metastatic gastrinoma with secretory differentiation to ACTH. ( 27060354 )
2016
16
Metastatic gastrinoma in the breast mimicking primary solid papillary carcinoma. ( 27342908 )
2016
17
Synchronous Peripancreatic Lymph Node Gastrinoma and Gastric Neuroendocrine Tumor Type 2. ( 27209642 )
2016
18
Sporadic, Primary Lymph Node Gastrinoma. ( 27457843 )
2016
19
Management of pancreatic gastrinoma associated with Von Hippel-Lindau disease: a case report. ( 27055912 )
2016
20
Medical management of gastrinoma in a cat. ( 28491421 )
2016
21
Primary lymph node gastrinoma: 2 cases and a review of the literature. ( 25623161 )
2015
22
Diagnosis and preoperative tagging of duodenal gastrinoma by endoscopic ultrasound. ( 26492296 )
2015
23
Chromogranin A in gastrinomas: Promises and pitfalls. ( 25861845 )
2015
24
Primary Hepatic Gastrinoma. ( 26556475 )
2015
25
Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma. ( 25625026 )
2015
26
Zollinger-Ellison syndrome: Revelation of the gastrinoma triangle. ( 27408649 )
2015
27
Intraoperative Use of a Portable Large Field of View Gamma Camera and Handheld Gamma Detection Probe for Radioguided Localization and Prediction of Complete Surgical Resection of Gastrinoma: Proof of Concept. ( 26206636 )
2015
28
Primary jejunal gastrinoma: a case report and review of the literature. ( 26546053 )
2015
29
Intraoperative near-infrared fluorescence visualization of theA duodenal gastrinoma in a patient withA Zollinger-Ellison syndrome. ( 26209566 )
2015
30
Impact of a novel 14a88bp MEN1 deletion in a patient with hyperparathyroidism and gastrinoma. ( 26191410 )
2015
31
Surgery for gastrinoma: Short and long-term results. ( 25748044 )
2015
32
Laparoscopic-assisted pancreaticoduodenectomy in a child with gastrinoma. ( 26711921 )
2015
33
An esophageal gastrointestinal stromal tumor in a patient with MEN1-related pancreatic gastrinoma: an unusual association and review of the literature. ( 25022420 )
2014
34
Metastatic gastrinoma in a pediatric patient with zollinger-ellison syndrome. ( 23426004 )
2014
35
Gastrinoma and neurofibromatosis type 2: the first case report and review of the literature. ( 24961548 )
2014
36
Deletions of RDINK4/ARF enhancer in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors. ( 25003221 )
2014
37
Case of primary hepatic gastrinoma: Diagnostic usefulness of the selective arterial calcium injection test. ( 25145887 )
2014
38
An evaluation of chromogranin A versus gastrin and progastrin in gastrinoma diagnosis and control. ( 24796622 )
2014
39
Misdiagnosed gastrinoma: A case report. ( 24932294 )
2014
40
Primary lymph node gastrinoma. A diagnosis of exclusion. A case for duodenotomy in the setting of a negative imaging for primary tumor: A case report and review of the literature. ( 25462049 )
2014
41
Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1. ( 22580937 )
2013
42
Gastroduodenal neuroendocrine neoplasms including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). ( 24431117 )
2013
43
Laparoscopic resection for primary lymph node gastrinoma. ( 23591435 )
2013
44
Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings. ( 22743840 )
2013
45
Biliary tree gastrinomas in multiple endocrine neoplasia type 1 syndrome. ( 24363522 )
2013
46
Multiple gastrinomas of the duodenum in a patient with sporadic Zollinger-Ellison syndrome. ( 23613167 )
2013
47
Criteria for the glucagon provocative test in the diagnosis of gastrinoma. ( 22983734 )
2013
48
Primary lymph node gastrinoma: a rare cause of abdominal pain in childhood. ( 23743959 )
2013
49
Lymph nodes metastasis and recurrences justify an aggressive treatment of gastrinoma. ( 23417896 )
2013
50
Primary hepatic gastrinoma as an unusual manifestation of zollinger-ellison syndrome. ( 23271988 )
2012

Variations for Gastrinoma

Cosmic variations for Gastrinoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM22579 MEN1 small intestine,duodenum,carcinoid-endocrine tumour,gastrinoma c.256A>T p.I86F 11:64809854-64809854 7
2 COSM521 KRAS small intestine,duodenum,adenoma,intestinal c.35G>A p.G12D 12:25245350-25245350 3
3 COSM532 KRAS small intestine,duodenum,adenoma,intestinal c.38G>A p.G13D 12:25245347-25245347 3

Expression for Gastrinoma

Search GEO for disease gene expression data for Gastrinoma.

Pathways for Gastrinoma

Pathways related to Gastrinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.2 GAST INS MEN1 NMB SCT SST
2 9.64 GAST SCT VIP

GO Terms for Gastrinoma

Cellular components related to Gastrinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.35 CHGA GAST INS SCT SST
2 extracellular region GO:0005576 9.17 CHGA GAST INS NMB SCT SST

Biological processes related to Gastrinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.43 INS NMB SST
2 G-protein coupled receptor signaling pathway GO:0007186 9.43 GAST INS NMB SCT SST VIP
3 regulation of protein localization GO:0032880 9.32 INS VIP
4 negative regulation of blood vessel diameter GO:0097756 9.16 CHGA INS
5 regulation of signaling receptor activity GO:0010469 9.1 GAST INS NMB SCT SST VIP

Molecular functions related to Gastrinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.1 GAST INS NMB SCT SST VIP

Sources for Gastrinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....